Eli Lilly’s oral GLP-1 therapy, orforglipron, met all primary and key secondary endpoints in the Phase III ACHIEVE-2 and ACHIEVE-5 studies, showing significant A1C reduction, weight loss, and ...

Key Takeaways A new ICD-10 diagnosis code, E11.A, now formally recognizes type 2 diabetes in remissionRemission requires an ...

Eli Lilly has built the case for its oral GLP-1 agonist orforglipron with two more phase 3 readouts, including new data ...

Hypothyroidism during pregnancy may have a negative metabolic impact in women with gestational diabetes, with high TSH levels ...

Eli Lilly (LLY) stock is in focus as the company's oral weight loss candidate orforglipron succeeds in two Phase 3 trials for ...

Eli Lilly has guided its oral GLP-1 drug candidate orforglipron through two more late-phase tests in Type 2 diabetes, racking ...

Type 1 diabetes wears many faces—an elusive autoimmune disease, a metabolic mess, a chronic condition that requires lifelong ...

An epidemic of Type 2 diabetes continues to plague the United States, leading to calls for reassessing how the disease is ...

Eli Lilly's experimental weight-loss pill, orforglipron, demonstrated superior blood sugar control in late-stage trials involving diabetic patients.

During November, the American Red Cross is partnering with National Diabetes Month to offer free hemoglobin A1C testing to ...